Public Accounting, International Standards, and You: A Closer Look on the Impact of IFRS and GAAP Convergence by Lomo, Daniella
University of Connecticut
OpenCommons@UConn
Honors Scholar Theses Honors Scholar Program
Spring 5-2-2014
Public Accounting, International Standards, and
You: A Closer Look on the Impact of IFRS and
GAAP Convergence
Daniella Lomo
University of Connecticut - Storrs, daniella.lomo@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses
Part of the Accounting Commons
Recommended Citation
Lomo, Daniella, "Public Accounting, International Standards, and You: A Closer Look on the Impact of IFRS and GAAP
Convergence" (2014). Honors Scholar Theses. 341.
https://opencommons.uconn.edu/srhonors_theses/341
  
 
 
 
 
 
 
Public Accounting, International Standards, and You: 
A Closer Look on the Impact of IFRS and GAAP 
Convergence 
 
 
 
Daniella Lomo 
Honors Thesis 
University of Connecticut 
School of Business 
Accounting Department 
 
May 2014  
1 
 
Abstract 
The convergence of US GAAP and IFRS has been significant for the US Financial 
Accounting Standards Board (FASB) and the International Accounting Standards Board (IASB) 
over the decade. Due to major differences such as with the consolidation model and the special 
entities (i.e. Research and Development), there are concerns of how the convergence will affect 
the accounting practice. The US GAAP is known to have more industry-based details than the 
IFRS, and so it is essential to know what kind of issues lie from industry to industry. Here, our 
focus is within the life sciences. More specifically, this paper examines the financial statements 
of the top 10 firms in the pharmaceutical industry for both the United States and Europe. By 
analyzing and comparing the documentation, we can see the similarities and differences of using 
either the GAAP or IFRS. With these results, the impact of the convergence of the US GAAP 
and IFRS on the industry and as a whole will be concluded. 
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Introduction 
Public Accounting has faced many obstacles with the two different accounting standards 
used in the United States and Internationally. With different standards, two oversight groups 
were established, Financial Accounting Standards Board (FASB) and the International 
Accounting Standards Board (IASB). Thus, in September 2002 the IASB and the FASB agreed 
to work together, in consultation with other national and regional bodies, to remove the 
differences between international standards and US GAAP. This decision was embodied in a 
Memorandum of Understanding (MoU) between the boards known as the Norwalk Agreement.1 
The FASB’s mission is to improve U.S. financial accounting standards for the benefit of 
present and potential investors, lenders, donors, creditors, and other users of financial statements. 
The FASB believes that pursuing convergence – making global accounting standards as similar 
as possible – is fully consistent with that mission. Investors, companies, auditors, and other 
participants in the U.S. financial reporting system should benefit from the increased 
comparability that would result from internationally converged accounting standards. More 
comparable standards would reduce costs to both users and preparers of financial statements and 
make worldwide capital markets more efficient.2 
On the other hand, the IASB’s goal is to develop a single set of high quality, 
understandable, enforceable and globally accepted International Financial Reporting Standards 
(IFRSs) through its standard-setting body, the International Accounting Standards Board (IASB), 
as well as, promote the use and rigorous application of those standards.3 
                                                          
1 "Convergence between IFRSs and US GAAP." IFRS. <http://www.ifrs.org/Use-around-the-world/Global-
convergence/Convergence-with-US-GAAP/Pages/Convergence-with-US-GAAP.aspx>. 
2 "International Convergence of Accounting Standards - Overview." FASB. 25 Apr. 2014 
<http://www.fasb.org/jsp/FASB/Page/SectionPage%26cid%3D1176156245663>. 
3 "About the IFRS Foundation and the IASB." IFRS. <http://www.ifrs.org/The-organisation/Pages/IFRS-
Foundation-and-the-IASB.aspx>. 
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Convergence will move U.S. accounting from a detailed, rules-based approach to a more 
principles-based approach, and every aspect of operations will be affected. This makes the rules 
more difficult to apply initially, because it offers few clear-cut answers to accounting questions. 
This difference will require companies to more strongly focus on the definition of their 
accounting policies, resulting in increased transparency of financial reporting and improved 
consistency across businesses, industries and countries.4 
Strict guidelines found under GAAP will no longer be followed if there is a change to 
IFRS. Thus, allowing organizations to their revenue recognition policies to make their financial 
statements look better. This will be good because of the discretion that managers can use to 
better recognize their revenues within their company.  With more choice comes less 
comparability even between companies with similar operations.  The disclosures under IFRS will 
help maintain some of the comparability because managers have to explain why they choose a 
particular method of revenue recognition. 
 Why is this topic important? Many factors including Globalization, the Sarbanes-Oxley 
Act, the SEC adoption of international standards, and the economic and financial meltdown in 
recent years have been exerting pressure on a number of countries, including the United States, 
to eliminate the gap between the International Financial Reporting Standards (IFRS) and the U.S. 
Generally Accepted Accounting Principles (GAAP).5 And it is a necessity to analyze the impact 
these changes may have on current and future employees in the accounting industry.  
Are we in need of a convergence of IFRS and GAAP? What will be the impact of the 
decided change to IFRS on major public accounting firms? What actions will these firms take to 
                                                          
4 "What companies need to know about the impending switch to IFRS." Smart Business. 7 July 2011. 
<http://www.sbnonline.com/2011/07/what-companies-need-to-know-about-the-impending-switch-to-ifrs/>. 
5 "The Impact of Combining The U.S. GAAP And IFRS." Investopedia. 15 Jan. 2014 
<http://www.investopedia.com/articles/economics/12/impact-gaap-ifrs-convergence.asp>. 
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adjust to the change? How will this affect public accounting within the next 5 years? More 
precisely, when looking at the pharmaceutical industry, what kind of impact could we expect for 
other industries? This paper will explain the differences between GAAP and IFRS, in order to 
understand why there is differences in revenue recognition and intangible assets, which are two 
major changes to occur in the pharmaceutical industry.  
GAAP vs IFRS 
The overarching difference between the two accounting standards is US GAAP is rule 
based and IFRS is principle based. The difference between these two approaches is on the 
methodology to assess an accounting treatment. Under U.S. GAAP, the research is more focused 
on the literature whereas under IFRS, the review of the facts pattern is more thorough. However, 
the professional judgment is not a new concept in the U.S. environment. The SEC is addressing 
this topic in order to find the right balance between the “educated” professional judgment, that is 
acceptable, and the “guessed” professional judgment.6 
The IFRS project is the first step at trying to internationalize global accounting standards 
to be used by all companies both inside and outside the United States. Presently, United 
Kingdom companies are governed by IFRS issued by the International Accounting Standards 
Board (IASB). Effective in 2005, all companies listed on European stock exchanges 
(approximately 8,000) adopted IASB standards. As of 2010, approximately 120 countries 
required or allowed their companies to adopt the new international standards including the U.K., 
Australia, Japan, and New Zealand. Chile and South Korea adopted IFRS in 2009, Brazil in 
2010, Canada and India in 2011, and Mexico adopted starting in 2012. Japan will decide in 2012 
                                                          
6 "Is IFRS That Different From U.S. GAAP?" AICPA | www.IFRS.com. 16 June 2008. 
<http://www.ifrs.com/overview/General/differences.html>. 
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about an adoption in 2015 or 2016. A total of more than 12,000 companies are now using IFRS 
worldwide.7 
 With such a project, there have been many supporters. For example, CEO of Speed Tax, 
Anton Donde, stated I support the creation of a single set of global accounting standards -- and 
truly believe IFRS is way overdue. A single set of standards will not only simplify the way 
companies conduct themselves, but encourage 100 percent adoption of ethical behavior. In 
addition, any time somewhat-disparate regulatory bodies can come together for a common cause 
-- even though the rules may be somewhat complicated to follow in the short term -- the public 
will appreciate the effort because it builds long-term trust and a much stronger economy.8 
Pharmaceutical Industry Analysis 
 The pharmaceutical industry has four major processes in its value chain — discovery, 
development, manufacturing, and marketing and sales. Each of these processes is vital for the 
success of a pharmaceutical company. In some cases, a large, vertically-integrated 
pharmaceutical firm carries out a lot of these functions. Sometimes, however, certain activities 
are contracted or outsourced to other firms. The trend of outsourcing has grown over the past 
decade. Outsourcing of drug development to contract research organizations (CROs), or 
manufacturing to contract manufacturing organizations (CMOs), is common and has led to the 
development of a new industry known as contract research and manufacturing services 
(CRAMS). The pharmaceutical industry environment is complex, and requires pharmaceutical 
companies to balance various aspects of their business. The Pharmaceutical industry is 
                                                          
7 Top accounting issues for 2013: CPE course. Chicago: CCH, 2013. 
8 "IFRS - Convergence or Adoption?" Accounting Today News. 14 Sept. 2010. 
<http://www.accountingtoday.com/news/IFRS-Convergence-Adoption-55554-1.html>. 
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characterized by significant research and development spends, heavy regulations surrounding 
research, clinical trials, drug manufacture and sales and marketing practices and pricing.9 
 Below is a list of global pharmaceutical companies and the accounting standard that they 
follow: 
Company Standard Used Company Standard Used 
Actelion US GAAP Genetech, Inc. US GAAP 
Amgen US GAAP GlaxoSmithKline IFRS 
AstraZeneca IFRS Roche IFRS 
Allergan US GAAP Johnson & Johnson US GAAP 
Bristol Myers Squibb US GAAP Merck & Co., Inc. US GAAP 
Celgene US GAAP Novartis IFRS 
Elan Corp. IFRS Pfizer US GAAP 
Eli Lilly US GAAP Sanofi-Aventis IFRS 
 
Using this information, the annual reports for the top pharmaceutical companies within the US 
and Europe were analyzed for differences between revenue recognition and intangible assets. As 
these are two important areas that have shown major variances, it is important to see the impact 
of these areas between the different companies.  
Johnson & Johnson10 
 The Company recognizes revenue from product sales when goods are shipped or 
delivered, and title and risk of loss pass to the customer. Provisions for certain rebates, sales 
incentives, trade promotions, coupons, product returns and discounts to customers are accounted 
for as reductions in sales in the same period the related sales are recorded. 
Product discounts granted are based on the terms of arrangements with direct, indirect and other 
market participants, as well as market conditions, including prices charged by competitors. 
Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual 
                                                          
9 "Accounting and Auditing Update" KPMG. July 2010. 
10 Johnson & Johnson. Annual report 2013.  <http://www.investor.jnj.com/secfiling.cfm?filingID=200406-14-33> 
7 
 
terms, historical experience, trend analysis and projected market conditions in the various 
markets served. The Company evaluates market conditions for products or groups of products 
primarily through the analysis of wholesaler and other third-party sell-through and market 
research data, as well as internally generated information. 
 Sales returns are generally estimated and recorded based on historical sales and returns 
information. Products that exhibit unusual sales or return patterns due to dating, competition or 
other marketing matters are specifically investigated and analyzed as part of the accounting for 
sales return accruals. Sales returns allowances represent a reserve for products that may be 
returned due to expiration, destruction in the field, or in specific areas, product recall. The 
returns reserve is based on historical return trends by product and by market as a percent to gross 
sales. In accordance with the Company’s accounting policies, the Company generally issues 
credit to customers for returned goods. The Company’s sales returns reserves are accounted for 
in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. 
Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and 
Pharmaceutical segments are almost exclusively not resalable.  
 Promotional programs, such as product listing allowances and cooperative advertising 
arrangements, are recorded in the year incurred. Continuing promotional programs include 
coupons and volume-based sales incentive programs. The redemption cost of consumer coupons 
is based on historical redemption experience by product and value. Volume-based incentive 
programs are based on estimated sales volumes for the incentive period and are recorded as 
products are sold. The Company also earns service revenue for co-promotion of certain products. 
For all years presented, service revenues were less than 2% of total revenues and are included in 
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sales to customers. These arrangements are evaluated to determine the appropriate amounts to be 
deferred. 
 During the fiscal first quarter of 2013, the Company adopted the Financial Accounting 
Standards Board (FASB) guidance and amendments related to testing indefinite-lived intangible 
assets for impairment. Under the amendments in this update, an entity has the option to first 
assess qualitative factors to determine whether the existence of events or circumstances indicates 
that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after 
assessing the totality of events and circumstances, an entity concludes that it is not more likely 
than not that the indefinite-lived intangible asset is impaired, then the entity is not required to 
determine the fair value. However, if an entity concludes otherwise, then it is required to 
determine the fair value of the indefinite-lived intangible asset and perform the quantitative 
impairment test. An entity also has the option to bypass the qualitative assessment for any 
indefinite-lived intangible asset in any period and proceed directly to performing the quantitative 
impairment test. This update became effective for annual and interim impairment tests performed 
for fiscal years beginning after September 15, 2012. The adoption of this standard did not have a 
material impact on the Company’s results of operations, cash flows or financial position. 
Pfizer11 
 Pfizer records revenues from product sales when the goods are shipped and title passes to 
the customer. At the time of sale, we also record estimates for a variety of sales deductions, such 
as sales rebates, discounts and incentives, and product returns. When we cannot reasonably 
estimate the amount of future product returns and/or other sales deductions, we record revenues 
when the risk of product return and/or additional sales deductions has been substantially 
                                                          
11 Pfizer. Annual report 2013.  < http://www.pfizer.com/investors/sec_filings> 
9 
 
eliminated. We record sales of certain of our vaccines to the U.S. government as part of the 
Pediatric Vaccine Stockpile program; these rules require that for fixed commitments made by the 
U.S. government, we record revenues when risk of ownership for the completed product has 
been passed to the U.S. government. There are no specific performance obligations associated 
with products sold under this program. 
 These acquired assets are recorded at cost. Intangible assets with finite lives are 
amortized on a straight-line basis over their estimated useful lives. Intangible assets with 
indefinite lives that are associated with marketed products are not amortized until a useful life 
can be determined. Intangible assets associated with IPR&D projects are not amortized until 
approval is obtained in a major market, typically either the U.S. or the European Union (EU), or 
in a series of other countries, subject to certain specified conditions and management judgment. 
The useful life of an amortizing asset generally is determined by identifying the period in which 
substantially all of the cash flows are expected to be generated. 
Merck & Co., Inc.12 
 Revenues from sales of products are recognized at the time of delivery when title and risk 
of loss passes to the customer. Recognition of revenue also requires reasonable assurance of 
collection of sales proceeds and completion of all performance obligations. Domestically, sales 
discounts are issued to customers as direct discounts at the point-of-sale or indirectly through an 
intermediary wholesaler, known as chargebacks, or indirectly in the form of rebates. 
Additionally, sales are generally made with a limited right of return under certain conditions. 
Revenues are recorded net of provisions for sales discounts and returns, which are established at 
                                                          
12 Merck & Co., Inc. Annual report 2013.  < http://www.merck.com/investors/financials/annual-reports/home.html> 
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the time of sale. In addition, revenues are recorded net of time value of money discounts if 
collection of accounts receivable is expected to be in excess of one year. 
 Acquired intangibles include products and product rights, trade names and patents, which 
are recorded at fair value, assigned an estimated useful life, and are amortized primarily on a 
straight-line basis over their estimated useful lives ranging from 3 to 40 years. Merck 
periodically evaluates whether current facts or circumstances indicate that the carrying values of 
its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an 
estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is 
compared to the carrying value to determine whether an impairment exists. If the asset is 
determined to be impaired, the loss is measured based on the difference between the carrying 
value of the intangible asset and its fair value, which is determined based on the net present value 
of estimated future cash flows. 
Novartis13 
 Revenue is recognized on the sale of Novartis Group products and services and recorded 
as "Net sales" in the consolidated income statement when there is persuasive evidence that a 
sales arrangement exists, title and risks and rewards for the products are transferred to the 
customer, the price is determinable and collectability is reasonably assured. When contracts 
contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance 
criteria. For surgical equipment this occurs when title and risk and rewards are transferred after 
installation and any required training has been completed. For surgical equipment leased to 
customers, revenue representing the net present value of the minimum lease payments is 
recognized at the commencement of the lease term if the lease term is for the major part of the 
                                                          
13 Novartis. Annual report 2013. 
<http://www.sec.gov/Archives/edgar/data/1114448/000104746914000415/a2217883z20-f.htm> 
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economic life of the asset or if the payments represent substantially most of its fair value, even if 
the legal ownership is not transferred. If products are stockpiled at the request of the customer, 
revenue is only recognized once the products have been inspected and accepted by the customer 
and there is no right of return or replenishment on product expiry and cost of storage will be paid 
by the customer on normal commercial terms. 
 Cash discounts are offered to customers to encourage prompt payment and are recorded 
as revenue deductions. Wholesaler shelf-inventory adjustments are granted to customers based 
on the existing inventory of a product at the time of decreases in the invoice or contract price of a 
product or at the point of sale if a price decline is reasonably estimable. When there is historical 
experience of Novartis agreeing to customer returns or Novartis can otherwise reasonably 
estimate expected future returns, a provision is recorded for estimated sales returns. In doing so 
the estimated rate of return is applied, determined based on historical experience of customer 
returns or considering any other relevant factors. This is applied to the amounts invoiced also 
considering the amount of returned products to be destroyed versus products that can be placed 
back in inventory for resale. Where shipments are made on a re-sale or return basis, without 
sufficient historical experience for estimating sales returns, revenue is only recorded when there 
is evidence of consumption or when the right of return has expired. 
 Intangible assets available for use are amortized over their estimated useful lives on a 
straight-line basis and evaluated for potential impairment whenever facts and circumstances 
indicate that their carrying value may not be recoverable. 
 Acquired research and development intangible assets, which are still under development 
and have accordingly not yet obtained marketing approval, are recognized as In Process 
Research & Development (IPR&D). IPR&D assets are only capitalized if they are deemed to 
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enhance the intellectual property of Novartis and include items such as initial upfront and 
milestone payments on licensed or acquired compounds. IPR&D is not amortized, but evaluated 
for potential impairment on an annual basis or when facts and circumstances warrant. Any 
impairment charge is recorded in the consolidated income statement under "Research & 
Development". Once a project included in IPR&D has been successfully developed it is 
transferred to the "Currently marketed product" category. 
Sanofi14 
 Revenue arising from the sale of goods is presented in the income statement under Net 
sales. Net sales comprise revenue from sales of pharmaceutical products, vaccines, and active 
ingredients, net of sales returns, of customer incentives and discounts, and of certain sales-based 
payments paid or payable to the healthcare authorities. Revenue is recognized when all of the 
following conditions have been met: the risks and rewards of ownership have been transferred to 
the customer; the Group no longer has effective control over the goods sold; the amount of 
revenue and costs associated with the transaction can be measured reliably; and it is probable 
that the economic benefits associated with the transaction will flow to the Group, in accordance 
with IAS 18 (Revenue). 
 Intangible assets are initially measured at acquisition cost or production cost, including 
any directly attributable costs of preparing the asset for its intended use, or (in the case of assets 
acquired in a business combination) at fair value as at the date of the combination. They are 
amortized on a straight line basis over their useful lives. The useful lives of intangible assets are 
reviewed at each reporting date. The effect of any adjustment to useful lives is recognized 
prospectively as a change of accounting estimate. 
                                                          
14 Sanofi. Annual report 2013. 
<http://en.sanofi.com/investors/news/financial_publications/financial_publications.aspx> 
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 Amortization of intangible assets is recognized in the income statement under 
Amortization of intangibles with the exception of amortization of acquired or internally-
developed software, which is recognized on the relevant line of the income statement according 
to the purpose for which the software is used. The group does not own any intangible assets with 
an indefinite useful life. Intangible assets are carried at cost less accumulated amortization and 
accumulated impairment, if any, in accordance with IAS 36 
GlaxoSmithKline15 
 Revenue is recognized in the income statement when goods or services are supplied or 
made available to external customers against orders received, title and risk of loss is passed to 
the customer, reliable estimates can be made of relevant deductions and all relevant obligations 
have been fulfilled, such that the earnings process is regarded as being complete. 
 Intangible assets are stated at cost less provisions for amortization and impairments. 
Licenses, patents, know-how and marketing rights separately acquired or acquired as part of a 
business combination are amortized over their estimated useful lives, generally not exceeding 20 
years, using the straight-line basis, from the time they are available for use. The estimated useful 
lives for determining the amortization charge take into account patent lives, where applicable, as 
well as the value obtained from periods of non-exclusivity. Asset lives are reviewed, and where 
appropriate adjusted, annually. Contingent milestone payments are recognized at the point that 
the contingent event becomes certain. Any development costs incurred by GlaxoSmithKline and 
associated with acquired licenses, patents, and know-how or marketing rights are written off to 
the income statement when incurred, unless the criteria for recognition of an internally generated 
                                                          
15 GlaxoSmithKline. Annual report 2013. <http://www.gsk.com/investors/corporate-reporting/annual-report.html> 
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intangible asset are met, usually when a regulatory filing has been made in a major market and 
approval is considered highly probable. 
 Acquired brands are valued independently as part of the fair value of businesses acquired 
from third parties where the brand has a value which is substantial and long-term and where the 
brands either are contractual or legal in nature or can be sold separately from the rest of the 
businesses acquired. Brands are amortized over their estimated useful lives of up to 20 years, 
except where it is considered that the useful economic life is indefinite. 
 The costs of acquiring and developing computer software for internal use and internet 
sites for external use are capitalized as intangible fixed assets where the software or site supports 
a significant business system and the expenditure leads to the creation of a durable asset. ERP 
systems software is amortized over seven to ten years and other computer software over three to 
five years. 
 The US based pharmaceutical companies compared to the European pharmaceutical 
companies show two difference consistent approaches to revenue recognition and intangible 
assets. The following sections will elaborate on differences found using GAAP and IFRS. 
Revenue Recognition 
Revenue is a crucial number to users of financial statements in assessing an entity’s 
financial performance and position. However, revenue recognition requirements in U.S. 
generally accepted accounting principles (GAAP) differ from those in International Financial 
Reporting Standards (IFRSs), and both sets of requirements need improvement. U.S. GAAP 
comprises broad revenue recognition concepts and numerous requirements for particular 
industries or transactions that can result in different accounting for economically similar 
transactions. Although IFRSs have fewer requirements on revenue recognition, the two main 
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revenue recognition standards, IAS 18, Revenue, and IAS 11, Construction Contracts, can be 
difficult to understand and apply. 
Revenue recognition guidance under IFRS is provided principally by International 
Accounting Standard (IAS) 18 Revenue. IAS 18 provides guidance on revenue recognition for 
the provision of both goods and services. IAS11 also provides guidance but specifically in 
relation to construction contracts and will usually not be applicable to most agreements 
encountered in the pharmaceutical and biotechnology industries. Its requirements are, however, 
applied by analogy through IAS 18.21.Under IFRS, revenue is recognized when it is probable 
that future economic benefits will flow to the entity and those benefits can be measured reliably. 
Revenue on sales of goods is only recognized when, inter alia, the significant risks and rewards 
of ownership have been transferred to the buyer and the seller does not retain either control of 
the goods, or continuing involvement, to the degree associated with ownership. For services, 
evidence is required that a service has been delivered by requiring the seller to be able to 
measure reliably the stage of completion of the transaction. In the pharmaceuticals industry it is 
important to assess whether the selling entity has actually delivered something – either 
transferring the risks and rewards of goods or other assets (e.g. licenses) or by providing service 
to the buyer.16 Differences between US GAAP and IFRS under revenue recognition is as 
follows: 
 
 US GAAP IFRS Major Difference 
Sale of Goods SAB 104, Revenue 
Recognition, requires 
the risks and rewards 
of ownership have 
been transferred 
(delivered). 
Revenue is 
recognized when 
risks and rewards of 
ownership have 
been transferred and 
Under GAAP, 
revenue is not 
recognized prior 
to delivery. While, 
IFRS may 
recognize prior to 
                                                          
16 "International Financial Reporting Standards." PwC. July 2012 
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the buyer has control 
of the goods.  
delivery if risks 
and rewards have 
been transferred to 
buyer.  
Research and 
Development & 
Services 
Service revenues is 
recognized in 
accordance to SAB 
104.   
Revenue may be 
recognized with 
long term 
accounting. Thus, 
consideration for 
stage of completion 
is needed to 
determine revenue 
and costs reliably.  
Revenue is not 
recognized until 
service is 
completed under 
GAAP. IFRS 
recognizes upfront 
revenue.  
 
Intangible Assets 
 
 Research & Development (R&D) activities are critical to the success of the life sciences 
industry. Life sciences companies invest a significant amount of capital to research, discover and 
clinically test new drug candidates in the hopes of generating future revenue. Accordingly, life 
sciences companies must carefully consider whether any US GAAP-IFRS differences exist 
relating to the accounting for intangible assets, including R&D costs. Some of the more 
significant GAAP differences may include the accounting for internal development costs and (ii) 
payments made to separately acquire or license intangible assets (for example, in a collaboration 
arrangement).17 Some significant differences found in intangible assets can be seen below: 
 US GAAP IFRS Major Difference 
Development Costs Costs are expensed as 
it is incurred.  
Costs are capitalized 
as long as specified 
criteria is met.  
Under IFRS, 
development costs 
will be recognized 
over multiple periods, 
where it does not 
under GAAP 
Payments (i.e. 
Milestone or license) 
Payments for rights 
to a product not yet 
received regulatory 
approval is expensed. 
 
Payments should be 
capitalized as 
intangible assets. 
Intangibles may be 
more accurately 
stated under IFRS.  
                                                          
17 "US GAAP vs IFRS: The Basics: Life Science." EY. June 2009  
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Payments for rights 
to a product that has 
received regulatory 
approval is 
capitalized. 
Advertising Costs Costs are either 
expensed as incurred 
or expense when it 
occurs for the first 
time.  
Costs are expensed as 
it is incurred. 
IFRS allows for 
prepayments to be 
recognized as well, if 
there is access to 
goods. 
Revaluations Revaluation is not 
allowed. 
Revaluation to fair 
value as an intangible 
asset is a permitted 
accounting policy.  
Intangibles may be 
more accurately 
stated under IFRS. 
 
Implementation 
Revenue Recognition 
 Current plans suggest a consistency in revenue recognition regardless of the industry. 
Organizations will be required to disclose quantitative information about contracts with 
customers, including disaggregation of revenue, contract balances and changes in those balances, 
remaining performance obligations and information about assets recognized from the costs to 
obtain or fulfill contracts with customers; and qualitative information about revenue contracts 
including significant judgments involved in applying the revenue guidance. 
 In addition, reporting organizations will be required to assess the goods or services 
promised to a customer, identify performance obligations on the basis of whether the goods or 
services are distinct, and recognize revenue when (or as) each performance obligation is 
satisfied. Companies will be required to allocate the transaction price to each performance 
obligation (or distinct good or service) in an amount that depicts the amount of consideration to 
which the entity expects to be entitled in exchange for transferring the promised goods or 
services to the customer. Variable consideration will be included in the transaction price to the 
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extent it is probable that a significant revenue reversal will not occur. Consideration can vary 
because of discounts, rebates, refunds, credits, price concessions, incentives, performance 
bonuses, penalties, or other similar items. 
 For public companies, the new guidance will be required for annual reporting periods 
beginning after December 15, 2016, including interim reporting periods within that reporting 
period. Early application is not permitted. For nonpublic companies, the new guidance will be 
required for annual reporting periods beginning after December 15, 2017, and interim and annual 
reporting periods after those reporting periods. A nonpublic entity may elect early application, 
but no earlier than the effective date for public entities. For companies reporting under IFRS, the 
new guidance will be required for reporting periods beginning on or after January 1, 2017. Early 
application is permitted.18 
 With such changes, it is necessary for a delayed effective date because of the various 
organizations that will be affected. These changes will also have a significant effect on other 
areas of their financial statements that are tied to revenue recognition. Time is needed in order to 
adjust to these changes.  
Intangible Assets 
 FASB and IASB have no longer made intangible assets a priority, even though the 
convergence was mentioned in the “Memorandum of Understanding” (MOU) in 2006. 
Nonetheless, it was mentioned in the 2008 MOU that there is a possibility for a new project to 
eliminate differences in the accounting for research and development costs. Thoughts are 
formulated that the IAS 38 will be adopted in the future. 
                                                          
18 "Revenue Recognition." FASB, Financial Accounting Standards Board. 
<http://www.fasb.org/jsp/FASB/Page/BridgePage%26cid%3D1351027207987#section_6>. 
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 In March 2009, the FASB’s Emerging Issues Task Force tentatively concluded in EITF 
09-2 Research and Development Assets Acquired in an Asset Acquisition that research and 
development assets acquired in an asset acquisition should be capitalized. While the Task Force 
is in the early stages of its deliberations on the Issue, it could result in convergence for certain 
aspects of accounting for intangible assets that are significant for life sciences companies (for 
example, payments to acquire or in-license intangible assets, such as through R&D collaboration 
arrangements, would be capitalized, which is consistent with the accounting under IFRS).19 
Conclusion 
In summary, the accounting challenges in a pharmaceutical industry continue to be 
centered around revenue recognition (upfront vs. deferral), accounting for research and 
development (capitalize vs. expense) and intangible assets (amortize and carry forward vs. 
impair). Adoption of IFRS around the world is expected to introduce homogeneity in accounting 
practices and permit international comparability and thereby accelerate cross border 
transactions.20  
 As a result many benefits will be seen. By converging the US GAAP and IFRS, 
businesses will be able to present financial statements among foreign relations and it will allow 
for easier comparisons. Also, tying back to globalization, as many companies have subsidiaries 
in other countries, it allows for a consistent accounting standard to be used worldwide, instead of 
confusion within the company. To accommodate for the impact the changes may have, a steady 
gradual convergence is necessary. Nonetheless, the change will not be taken lightly by upper 
management who are thinking about cost effectiveness. It will also impact investors, stock 
markets, accounting professionals, and the accounting standard rule setters. 
                                                          
19 "US GAAP vs IFRS: The Basics: Life Science." EY. June 2009 
20 "Accounting and Auditing Update" KPMG. July 2010. 
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The program of converging accounting standards between the Financial Accounting 
Standards Board and the International Accounting Standards Board is nearing an end after more 
than a decade. Along the way there have been some bumps and differences in view between 
FASB and IASB, but this unique standard-setting partnership has resulted in converged or 
substantially converged standards on a number of major subjects, including accounting for 
business combinations, employee stock compensation, fair-value measurements, and segment 
reporting.21 
 
 
                                                          
21 Herz, Robert. "End of Convergence Brings Challenges and Opportunities." Compliance Week. 27 Aug. 2013. 
<http://www.complianceweek.com/end-of-convergence-brings-challenges-and-opportunities/article/307946/>. 
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